Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

Individuals can access the conference call by dialing:

US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297

Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
David Holmes
ir@standardbio.com

Staff

Recent Posts

cbdMD Achieves Key Milestone in UK Novel Food Regulatory Approval

FSA Publishes Safety Assessment for cbdMD's Proprietary CBD IngredientCharlotte, North Carolina--(Newsfile Corp. - April 7,…

25 minutes ago

Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP)…

26 minutes ago

FendX Provides Shareholder Update

Oakville, Ontario--(Newsfile Corp. - April 7, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

1 hour ago

Lenire Supports Veterans by Sponsoring Hearoes Tour

Lenire proudly sponsors the 10th Annual LexCare Hearing Foundation Hearoes Tour.Lenire is a treatment option…

1 hour ago

Millions of people unite around doing good on the 19th International Good Deeds Day held yesterday worldwide

Good Deeds Day continues to expand worldwide, as the peak event of year-round volunteer activities.…

1 hour ago

Philips Applauded by Frost & Sullivan for Improving Imaging Quality and Efficiency in Healthcare with Its CT 3500 Imaging Solution

Philips CT 3500, a scalable, adaptable, and durable imaging solution, improves efficiency and care quality,…

7 hours ago